Ibandronate set for filing in Japan following positive local trial
This article was originally published in Scrip
Executive Summary
Chugai/Roche's extended-release bisphosphonate product ibandronate sodium is set to be filed for osteoporosis in Japan next year following positive results from a local Phase II/III trial. The product is being co-developed and will be co-marketed with Taisho.